Zobrazeno 1 - 10
of 73
pro vyhledávání: '"33"'
Autor:
David Miles, Matthew Kent, Kenneth Russell, Mary K Downer, Patricia Luhn, Joyce O'Shaughnessy
Publikováno v:
Cancer Research. 80:P2-15
Background: Corticosteroids (CS) have immunosuppressive properties that may diminish the efficacy of cancer immunotherapy (CIT). In retrospective analyses of clinical trial data, the use of CS for immune-mediated adverse events after starting CIT doe
Autor:
Dongling Gao, Nan Dong, Yuchen Han, Ruiying Zhao, Xue Wu, Zhihua Zhao, Qiuxiang Ou, Wencai Li, Guozhong Jiang, Xiaoling Tong
Publikováno v:
Cancer Research. 80:741-741
Background ROS1 gene rearrangements are reported at a prevalence of 1-2% in unselected cancer populations including non-small cell lung cancer (NSCLC), and notably higher in lung adenocarcinoma. More than twenty ROS1 fusion partners have been identif
Autor:
Sulan Yao, Jian Zhang, Xuejun Liang, Leiping Wang, Yanping Ji, Feng Tian, Xichun Hu, Gang Xia, Gaozhun Xiong
Publikováno v:
Cancer Research. 81:PS10-57
Background: ARX788 is a novel antibody drug conjugate (ADC) that consists of a human epidermal growth factor receptor 2 (HER2) targeting monoclonal antibody (mAb) site-specifically conjugated with payload AS269, a highly potent tubulin inhibitor. Res
Autor:
Leonardo Fleury Orlandini, Francisco Jc dos Reis, Jurandyr Moreira de Andrade, Franklin F Pimentel, Daniel Guimarães Tiezzi, Hélio Ha Carrara
Publikováno v:
Cancer Research. 80:P2-08
Background: Despite of several studies described body mass index (BMI) as a poor prognostic factor in breast cancer (BC) patients, the available data are still conflicting and the relation between obesity and BC remains unclear. In this study we eval
Publikováno v:
Cancer Research. 80:P2-14
Background: Older patients with early breast cancer (EBC) are a heterogenous population which is often treated less aggressively than their younger counterparts. This may lead to increased variance in the use of adjuvant systemic therapy and conseque
Autor:
P Ganschow, P Nagireddy
Publikováno v:
Cancer Research. 79:P5-09
Background: Hereditary cancer syndromes account for 5-10% of cancers. Limited data exists on the uptake of genetic testing and the prevalence of mutations in minority populations. Objective: To estimate genetic testing uptake and prevalence of mutati
Autor:
Junji Tsurutani, Haeseong Park, S. Takahashi, Yoshiaki Sagara, H. Iwata, Kazuo Tamura, Charles H. Redfern, Masahiro Sugihara, Toshihiko Doi, Rashmi Krishna Murthy, Alvaro Moreno-Aspitia, Shanu Modi, Ian E. Krop, Yoshihiko Fujisaki, Caleb Lee, Rebecca Redman
Publikováno v:
Cancer Research. 79:P6-17
Background: HER2-targeted therapies have improved survival for advanced HER2-positive breast cancers (BC), but none have been approved for tumors with low levels of HER2 expression (ie, HER2 IHC 1+ or 2+/ISH-negative). Trastuzumab deruxtecan (DS-8201
Publikováno v:
Cancer Research. 69:1014-1014
Background: Sentinel lymph node biopsy (SLNB) for breast cancer patients before chemotherapy is currently being practiced in a world wide scale. However, obvious disadvantage of a second surgical procedure after neoadjuvant chemotherapy (NAC) has bee
Autor:
Lalit Dar, Sunil K. Pati, Alka Kriplani, Neerja Bhatla, A. Raj Kumar Patro, Shobha Broor, Arti Gulati, Pankaj Kumar
Publikováno v:
Cancer Research. 69:C59-C59
Background: Cervical cancer caused by human papilloma virus (HPV), is the commonest cancer in Indian women, with an estimated 132000 new cases and 76000 deaths annually. More than 100 HPV genotypes have been identified in humans of which at least 40
Autor:
Matthew J. Ellis, Jo Anne Zujewski, Monica M. Mita, J. M. Guenther, Wajeeha Razaq, Anna Weiss, Kelly K. Hunt, T Dockter, Cynthia X. Ma, Olwen Hahn, Lisa A. Carey, Mark A. Watson, S Sanati, Horacio Maluf, Vera J. Suman, Yang Wang, Jeremy Hoog, Kiran Vij, Clifford A. Hudis, Gary Unzeitig, Tina J. Hieken, Amy Tiersten, Eric P. Winer, Ann H. Partridge, Erika C. Crouch, A. Marilyn Leitch, Abigail S. Caudle
Publikováno v:
Cancer Research. 81:GS4-05
Background: Ki67 values >10% 2-4 weeks (wks) after starting neoadjuvant ET (NET) indicates persistent cell proliferation, resistance to ET, and is associated with increased risk of recurrence. The ACOSOG Z1031 trial suggested that these tumors are al